Olanzapine vs. lithium in management of acute mania

Shafti, Saeed Shoja

doi:10.1016/j.jad.2009.08.013

Cited by 27 publications

(19 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lithium was found to have equal efficacy to carbamazepine (Lerer et al, 1987; Okuma et al, 1990; Small et al, 1991), olanzapine (Berk et al, 1999; Niufan et al, 2008; Shafti, 2010), quetiapine (Bowden et al, 2005b; Li et al, 2008), and aripiprazole (Keck et al, 2009). In severely psychotic patients, it seems inferior to haloperidol (Shopsin et al, 1975; Garfinkel et al, 1980).…”

Section: Efficacy Datamentioning

confidence: 99%

The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm

Fountoulakis

Yatham

Grunze

et al. 2016

IJNPPY

View full text Add to dashboard Cite

Background:The current paper includes a systematic search of the literature, a detailed presentation of the results, and a grading of treatment options in terms of efficacy and tolerability/safety.Material and Methods:The PRISMA method was used in the literature search with the combination of the words ‘bipolar,’ ‘manic,’ ‘mania,’ ‘manic depression,’ and ‘manic depressive’ with ‘randomized,’ and ‘algorithms’ with ‘mania,’ ‘manic,’ ‘bipolar,’ ‘manic-depressive,’ or ‘manic depression.’ Relevant web pages and review articles were also reviewed.Results:The current report is based on the analysis of 57 guideline papers and 531 published papers related to RCTs, reviews, posthoc, or meta-analysis papers to March 25, 2016. The specific treatment options for acute mania, mixed episodes, acute bipolar depression, maintenance phase, psychotic and mixed features, anxiety, and rapid cycling were evaluated with regards to efficacy. Existing treatment guidelines were also reviewed. Finally, Tables reflecting efficacy and recommendation levels were created that led to the development of a precise algorithm that still has to prove its feasibility in everyday clinical practice.Conclusions:A systematic literature search was conducted on the pharmacological treatment of bipolar disorder to identify all relevant random controlled trials pertaining to all aspects of bipolar disorder and graded the data according to a predetermined method to develop a precise treatment algorithm for management of various phases of bipolar disorder. It is important to note that the some of the recommendations in the treatment algorithm were based on the secondary outcome data from posthoc analyses.

show abstract

Section: Efficacy Datamentioning

confidence: 99%

The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm

Fountoulakis

Yatham

Grunze

et al. 2016

IJNPPY

View full text Add to dashboard Cite

show abstract

“…Lithium was also found to be equal to olanzapine [61] but may be less efficacious in specific populations like those with mixed features. A small study suggested that lithium might have some advantages over olanzapine [445]. One more recent study reported that aripiprazole was equal to lithium but aripiprazole acted faster [274,282].…”

Section: Comparison Of Treatmentsmentioning

confidence: 99%

Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry

Fountoulakis

Kasper

Andreassen

et al. 2012

Eur Arch Psychiatry Clin Neurosci

116

View full text Add to dashboard Cite

“…Over the years, a number of psychopharmacological agents have been introduced, with lithium (Li) cation being one of the most promising and effective, primarily in the recovery of bipolar affective disorder [1]. However, its potential therapeutic application spectra are much wider with evidence supporting its use in the treatment of unipolar depression [2], acute mania and its prophylactic [3,4], or reduction in suicidal and aggressiveness rates in affective disorders [5,6] and conduct disorder [7]. It is also speculated whether Li could be used in treating neurodegenerative disorders including Alzheimer's disease and, importantly, its prevention [8].…”

Section: Introductionmentioning

confidence: 99%

Cultivation of mushrooms for production of food biofortified with lithium

Mleczek

Siwulski

Rzymski

et al. 2016

Eur Food Res Technol

View full text Add to dashboard Cite

investigated mushroom species in various cultures as food or alternative medicines, their Li-biofortified forms could potentially find social acceptance. The concentrations of Li accumulated in fruiting bodies were not high enough for application in psychiatric treatments but could potentially support the daily intake of Li for behavior modification or health beneficiary purposes. Further studies are necessary to fully investigate the safety implications of Li-enriched mushrooms for humans.

show abstract

Olanzapine vs. lithium in management of acute mania

Cited by 27 publications

References 10 publications

The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm

The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm

Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry

Cultivation of mushrooms for production of food biofortified with lithium

Contact Info

Product

Resources

About